文献速递乳腺癌支持与姑息治疗

曲妥珠单抗治疗相关左心室功能障碍:一级预防是最佳选择吗?

Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?
PubMed 文献 · J Clin Oncol · 2016-12-28

本文为肿瘤学大查房系列文章,通过一例51岁HER2阳性乳腺癌患者接受FEC方案后序贯多西他赛联合曲妥珠单抗治疗的病例,阐述曲妥珠单抗相关左心室功能障碍的诊断与管理挑战,并综述相关文献及作者建议的管理方法。

要点

  • 病例为51岁女性,左侧T2N1、3级、ER/PR阴性、HER2阳性乳腺癌,计划接受FEC方案3周期后序贯多西他赛联合曲妥珠单抗3周期,再维持曲妥珠单抗至1年。
  • 基线超声心动图显示左心室射血分数61%,整体纵向应变-21.5%,心脏磁共振成像、高敏肌钙蛋白I和B型利钠肽作为监测手段。
  • 文章讨论是否可使用药物预防蒽环类和曲妥珠单抗治疗相关的罕见但严重的充血性心力衰竭并发症。

核心结论

  • 文章通过病例展示和文献回顾,讨论曲妥珠单抗治疗相关左心室功能障碍的一级预防策略选择。

研究设计与样本

  • 肿瘤学大查房系列文章,包含病例 presentation、诊断与管理挑战描述、相关文献综述及作者建议的管理方法总结。

主要发现

  • 病例为51岁女性,左侧T2N1、3级、雌激素受体和孕激素受体阴性、人表皮生长因子受体2(HER2)阳性乳腺癌,计划接受3周期FEC(氟尿嘧啶、表柔比星[100 mg/m2每剂]和环磷酰胺)后序贯3周期多西他赛联合曲妥珠单抗,再维持曲妥珠单抗至完成1年疗程。
  • 患者无既往心血管疾病、高血压、糖尿病或高胆固醇血症病史,不吸烟,初始就诊血压138/84,心血管检查无异常,超声心动图显示正常窦性心律73次/分。
  • 治疗期间监测包括超声心动图(基线左心室射血分数61%,整体纵向应变-21.5%)、心脏磁共振成像(作为正在进行研究的一部分)、高敏肌钙蛋白I和B型利钠肽。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 51-year-old women with left-sided, T2N1, grade 3, estrogen receptor- and progesterone receptor-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer was referred to a cardio-oncology clinic for pre-cancer treatment cardiovascular risk assessment. The planned cancer treatment was 3 cycles of FEC (fluorouracil, epirubicin [100 mg/m2 per dose], and cyclophosphamide), followed by 3 cycles of concurrent docetaxel and trastuzumab, followed by maintenance trastuzumab to complete a 1-year course. Other than a prior history of hysterectomy, there was no relevant medical history. Her cardiac history was notable for the absence of prior cardiovascular disease, hypertension, diabetes, or hypercholesterolemia. She was a nonsmoker. At initial clinic visit, her blood pressure was 138/84 with an unremarkable cardiovascular examination. Her echocardiography demonstrated normal sinus rhythm at 73 beats per minute. During cancer treatment, she was observed with echocardiography (baseline left ventricular ejection fraction [LVEF], 61%; global longitudinal strain, -21.5%), cardiac magnetic resonance imaging (CMR, as part of an ongoing study), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ). Given that her baseline evaluations were negative at her initial visit, we discussed whether there were agents to prevent the rare, but serious, complication of congestive heart failure (HF) associated with anthracycline- and trastuzumab-based therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Thavendiranathan P, Amir E. Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option? J Clin Oncol. 2016. PMID: 28029315. doi:10.1200/JCO.2016.71.0038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。